Outcomes in a warfarin-treated population with atrial fibrillation

JAMA Cardiology

Volumn 1, Issue 2, 2016, Pages 172-180

  Björck, Fredrik ^a   Renlund, Henrik ^b   Lip, Gregory Y H ^c,d   Wester, Per ^a,e   Svensson, Peter J ^f   Själander, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d AALBORG UNIVERSITY   (Denmark)

^e DANDERYD HOSPITAL   (Sweden)

^f LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PHARMACOKINETIC PARAMETERS; PROGNOSIS; RETROSPECTIVE STUDY; SWEDE (PEOPLE); THROMBOEMBOLISM; TIME IN THERAPEUTIC RANGE; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RISK FACTOR; SWEDEN; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SWEDEN; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84982911797     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.0199     Document Type: Article

References (42)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8):983-988.
2. Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14(10):1385-1413.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-867.
4. Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care. 2007; 25(2):123-128.
5. Själander A, Engström G, Berntorp E, Svensson P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med. 2003; 254(5):434-438.
6. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008; 179(3):235-244.
7. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007; 120(8): 700-705.
8. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008; 1(2):84-91.
9. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009; 15(3):244-252.
10. Connolly SJ, Pogue J, Eikelboom J, et al.; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118(20):2029-2037.
11. Sjögren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin: a report from the Swedish quality register Auricula. Thromb Haemost. 2015; 113(6):1370-1377.
12. Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes. 2014; 7(5): 664-669.
13. Ibrahim S, Jespersen J, Poller L; European Action on Anticoagulation. The clinical evaluation of international normalized ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost. 2013; 11(8):1540-1546.
14. Lind M, Fahlén M, Kosiborod M, Eliasson B, Odén A. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res. 2012; 129(1):32-35.
15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69(3):236-239.
16. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry Auricul A. Eur Heart J. 2011; 32(18):2282-2289.
17. Wallentin L, Yusuf S, Ezekowitz MD, et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376(9745):975-983.
18. Björck F, Sandén P, Renlund H, Svensson PJ, Själander A. Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. Thromb Res. 2015; 136(2):216-220.
19. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012; 110(3): 453-460.
20. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921):955-962.
21. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-992.
22. Camm AJ. The RE-LY study: Randomized Evaluation of Long-term Anticoagulant Therapy: dabigatran vs. warfarin. Eur Heart J. 2009; 30(21): 2554-2555.
23. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-2104.
24. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
25. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999; 9(4):215-217.
26. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005; 143(4):241-250.
27. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006; 333(7571):726.
28. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-2194.
29. Auricula. Auricula Annual Report 2014 (Auricula Årsrapport 2014). UCR, Uppsala Clinical Research Center. http://www.ucr.uu.se/auricula/index.php/arsrapporter. Published 2014. Accessed September 23, 2015.
30. Grzymala-Lubanski B, Själander S, Renlund H, Svensson PJ, Själander A. Computer aided warfarin dosing in the Swedish national quality registry Auricul A-algorithmic suggestions are performing better than manually changed doses. Thromb Res. 2013; 131(2):130-134.
31. National Board of Health and Welfare (Socialstyrelsen). The Cause of Death Register. http://www.socialstyrelsen.se/statistics/statisticaldatabase/help/causeofdeath. Accessed December 2, 2015.
32. Swedish National Patient Register. The National Board of Health and Welfare (Socialstyrelsen). http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish. Accessed October 10, 2014.
33. Swedish Prescribed Drug Register. The National Board of Health and Welfare (Socialstyrelsen). http://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret. Accessed January 23, 2015.
34. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6)(suppl):257S-298S.
35. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692-694.
36. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III): position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013; 110(6):1087-1107.
37. De Caterina R, Ammentorp B, Darius H, et al.; PREFER in AF Registry Investigators. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014; 100(20):1625-1635.
38. Jun M, James MT, Manns BJ, et al.; Alberta Kidney Disease Network. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015; 350:h246.
39. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005; 36(7):1588-1593.
40. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010; 9(2):167-176.
41. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011; 11:450.
42. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al.; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014; 383(9913):245-254.